Precision Medicine Initiative (PMI) Committee Meeting

February 7, 2024

NIH NATIONAL CANCER INSTITUTE

Agenda –

- Role Call
- Project Updates
- CTEP CDISC Policy Governance Review
- Review Reassignment Workflow
- Review Cohort/Strata Updates
- Stakeholder Engagement Plan
- Project Status Updates

Stakeholder Representation

Project Updates

Project Updates – PMI Deliverables

	Deliverable	Target Release Date	Target Release Vehicle
☑	**ComboMATCH changes** (Disease fields, histology, behavior field code)	**PROD Released: July 17, 2023**	**Screening Protocol EC Template v2.0**
☑	**Designated Labs for Combo**	**PROD Released: Sept 6, 2023**	**Screening Protocol EC Template v3.0** *(UAT Release w/EA – 07/27/2023)*
☑	**Re-Screening ComboMATCH**	**PROD Released: Sept 27, 2023**	**MSRP Re-Screening EC Template v1.0** *(UAT Release w/EA – 07/27/2023)*
☑	**Cohort Migration**	**PROD OPEN Released: Sept 28, 2023** **PROD EC Temp v1.0 Released: *Oct 27, 2023***	**Treatment Protocol Cohort Migration EC Template v1.0**
☑	**MyeloMATCH Tx Protocol Crossover** (for S01, CTG01 and EA02)	*n/a*	Part of the existing Treatment Protocol workflow; no PRODUCTION OPEN Release required; the Westat team is prepared to support this workflow as Groups begin using it.
☑	**Re-Screening MM**	**PROD RS EC Temp v2.0 Released: *Nov 30, 2023***	No PRODUCTION OPEN Release is required for MM Re-Screening activities; the Westat team is prepared to support this workflow as Groups begin using it. **MSRP Re-Screening EC Template v2.0** *(UAT Release w/SWOG – 10/6/2023; 2nd UAT Release w/SWOG – 10/24/2023; 3rd UAT Release to SWOG – 11/07/2023; PROD RS EC Template v2.0 target date 11/30/2023)*
☐	**MyeloMATCH Stratification**	*PROD OPEN Release: February 12, 2023*	Part of existing Treatment Protocol Workflow.
☑	**BETA PMI Screening Protocol ALS v2.0** *New Forms: STMF, CLIA, PATH GROUP*	**Released:** *BETA Release: January 12, 2024*	Target date for BETA Release for Groups to initiate UAT activities. *(accompanied by BETA Screening Protocol Central Study ALS v2.0)*
☐	**PROD PMI Screening Protocol ALS v2.0** *New Forms: STMF, CLIA, PATH GROUP*	*PROD Release: April 22, 2024*	Target date for PRODUCTION Release for Groups to initiate implementation activities. *(accompanied by PROD Screening Protocol Central Study ALS v2.0)*

Project Updates - EC Template Release Schedule

Template	Version	UAT Release Date	PROD Release Date	Details
☑ **PMI Screening Protocol EC Template**	V1.0	Released: 12/16/2022	**Released: 02/15/2023**	
☑ PMI Screening Protocol EC Template	V2.0	Released: 05/01/2023	**Released: 07/17/2023**	Includes CM changes (Disease fields, histology, behavior field code)
☑ PMI Screening Protocol EC Template	V3.0	Released: 07/27/2023	**Released: 09/06/2023**	Includes updates for Designated Labs (DLAP fields)
☑ *PMI Screening Protocol EC Template Fact Sheet*	*v3.1*	*n/a*	*Released: 10/6/2023*	Administrative version/release of the Fact Sheet to capture MyeloMATCH Field Help/Instructional Text for the 'Prior therapy name' field; to be used in conjunction with the PMI Screening Protocol EC Template v3.0.
☑ **PMI Treatment Protocol EC Template**	V1.0	Released: 12/16/2022	**Released: 02/15/2023**	
☑ *PMI Treatment Protocol EC Template Fact Sheet*	*V1.1*	*n/a*	**Released:** *11/16/2023*	Administrative version/release of the Fact Sheet to provide a stand-alone TX Protocol-specific document allows Groups to easily access the Fact Sheet information; to be used in conjunction with the PMI Treatment Protocol EC Template v1.0.
☑ **PMI MSRP Re-Screening EC Template**	V1.0	Released: 07/27/2023	**Released: 09/27/2023**	*Supports ComboMATCH MSRP.*
☑ PMI MSRP Re-Screening EC Template	V2.0	Re-released: 11/07/2023 Re-released: 10/24/2023 Released: 10/06/2023	**Released**: **11/30/2023**	*Supports MyeloMATCH MSRP; PROD release date confirmed.*
☑ **PMI Treatment Protocol Cohort Migration EC Template**	V1.0	Released: 09/18/2023	**Released: 10/27/2023**	Supports cohort migration activities for ComboMATCH.
☑ *PMI Treatment Protocol Cohort Migration EC Template Fact Sheet*	*v1.1*	Re-Release: *10/4/2023*	**Released:** *10/27/2023*	Administrative version/re-release of the UAT Fact Sheet to capture updated Field Help/Instructional Text for the 'Cohort migration assignment' field; to be used in conjunction with the UAT PMI Treatment Protocol Cohort Migration EC Template v1.0.

Group UAT for MM

- Target date to complete UAT is 2/9/24
  - This will allow for time to perform FFP Testing and meet mid March MM activation

Group UAT Status : Screening Protocol ALS v2.0 (BETA)

- Beta ALSv2.0 Released on 1/15/24.
- Group UAT is underway
- Target date to complete Group UAT Testing (BETA) is **3/28/24**

ComboMATCH Priority 1 List

#	Protocol #	Protocol Title	Group	Activated	Current Status
1	EAY191	Molecular Analysis for Combination Therapy Choice (ComboMATCH)	ECOG-ACRIN	Yes	12/13: No Updates 1/10: No Updates 2/7: No Updates
2	EAY191-N4	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMATCH Treatment Trial	NRG	Yes	12/13: No Updates 1/10: No Updates 2/7: No Updates
3	EAY191-E4	A ComboMATCH Treatment Trial ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors	ECOG-ACRIN	Yes	12/13: No Updates 1/10: No Updates 2/7: No Updates
4	EAY191-N2	A ComboMATCH Treatment Trial EAY191-N2: Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1	NRG	Yes	12/13: Protocol amendment resubmitted. 1/10: No Updates 2/7: Got comments from Amendment 1, need to update EC template and need an updated protocol
5	EAY191-S3	Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors	SWOG	Yes	12/13: No Updates 1/10: No Updates 2/7: Removed the SSN and full name and released

ComboMATCH Priority 2 List

#	Protocol #	Protocol Title	Group	Activated	Current Status
6	EAY191-A6	A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations	Alliance	Yes	12/13: No Update 1/10: No Updates 2/7: No Updates
7	EAY191-A3	Palbociclib and Binimetinib in RAS-Mutant Cancers	Alliance	Yes	12/13: No Update 1/10: No Updates 2/7:No Updates

ComboMATCH Priority 3 List

#	Protocol #	Protocol Title	Group	Current Status
8	EAY191-A2	Olaparib Plus Low-Dose Alpelisib for Breast Cancer	Alliance	**11/1: Dropped** **1/10: No Updates** **2/7:**
9	EAY191-C1	Phase 2 Subprotocol of the Combination of a MEK Inhibitor and a Pan-RAF Inhibitor in Patients with Relapsed/Refractory Tumors Harboring Activating MAPK Pathway Mutations	COG	**12/13: Received confirmation will no longer be a CM Study, moving to a COG study.** **1/10: No Updates** **2/7: Dropped**
10	EAY191-E5	ComboMATCH Treatment Trial E5: A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors	ECOG-ACRIN	**12/13: Almost complete with internal OPEN testing; contacting CTSU and Engineering for FFP Cohort Migration.** **1/10: No Updates** **2/7: Active**
11	EAY191-N5	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N5: A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors A ComboMATCH Treatment Trial	NRG	**12/13: Updated protocol submitted to CTEP on 12/4. Waiting to get test patients and working on the build.** **1/10: No Updates** **2/7: Released to production of 2/12**

MyeloMATCH Priority 1 List

#	Protocol #	Protocol Title	Group	Current Status
1	MYELOMATCH	Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials	SWOG	**12/13: Completed testing.** **1/10: No Updates** **2/7: SWOG sent wording suggestions on site notification in November; need feedback on messages** **Sent a message about MM data that may need since SWOG, if we download from the portal – we have to pay for specimens** **Dialogue box in OPEN where you add the path report – Redaction instruction;**
2	MM1YA-S01	A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger with High-Risk (Adverse) Acute Myeloid Leukemia; A MYELOMATCH Clinical Trial	SWOG	**12/13: Delay because study structure; removing step 2 enrollment so SWOG has to redo work before they can move forward.** **1/10: No Updates** **2/7: Ready for MATCHbox integration testing on Jan 29.**
3	MM1YA-CTG01	A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial	CCTG	**12/13: Testing in progress** **1/10: No Updates** **2/7: Testing should be done soon, MATCHbox Integration Testing – Send over instructions -**
6	MM1OA-EA02	A Randomized Phase II Study of HMA-Based Therapies for the Treatment of Older Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia: A myeloMATCH Treatment Trial	ECOG-ACRIN	**12/13: Working on getting rando files to start OPEN testing** **1/10: No Updates** **2/7: Cohort/Stratum Assignment – Redoing the checklist – won't be ready for FFP by this week but working to meet that date.**

MyeloMATCH Priority 2 List

#	Protocol #	Protocol Title	Group	Current Status
4	MM2YA-EA01	Eradicating Measurable Residual Disease in Patients with Acute Myeloid Leukemia (AML) Prior to Stem Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial	ECOG-ACRIN	**1/10: No Updates** **2/7: No Updates**
5	MM1OA-S02	A Randomized Phase II Study of Targeted Agents with the Oral DNMT1 Inhibitor Cedazuridine-Decitabine (ASTX727) for the Treatment of Newly Diagnosed TP53-Mutated Acute Myeloid Leukemia in Older Patients: A myeloMATCH Treatment Trial	SWOG	**1/10: No Updates** **2/7: Started creating forms, waiting on integration testing to complete for SO1**
7	MM1MDS-EA03 (Concept	ERADICATE MDS with TP53 Study: Efficacy of targeted Agents Combinations with Oral DNMT1 Inhibitor C-DEC (ASTX727) for Treatment of Higher Risk Myelodysplastic Syndromes with TP53 Mutations: A Non-Comparative, Parallel, Multi-Arm Phase 2 Study	ECOG-ACRIN	**1/10: No Updates** **2/7:**

CTEP CDISC Policy Governance Review

Compliance for Use of ALS Versions

- Standard forms built in the LPO's Global Library within **60 days** of production ALS release to reflect additions/updates included in the ALS
  - Example: Release ALSv7.X on November 1, LPOs would be expected to incorporate the ALSv7.X into their Global Library by January 1
  - ALS versions for new study builds
    - LPOs will be required to use the most current version of the ALS available at the time of each study build

Reassignment Workflow

Reassignment Workflow - Phase 1

- The initial solution will address these use cases:
- For MM Only: the site started their participant on TAP treatment instead of enrolling to the assigned treatment protocol.

Scenario 1	Scenario 2:	Scenario 3:
• A site determines that the patient is ineligible for the MatchBox- assigned protocol	• The site does not have the MatchBox-assigned protocol opened	• The slot on the assigned treatment protocol has expired • *Note*: enabling this feature in production requires an amendment to the MSRP

OPEN Patient Summary Page – Request Button Placement



MatchBOX Assignments/Enrollments | Request Reassignment

Assignment:

Name	Value
Name	EAY191
Treatment assignment	EAY191-N2
Assignment status	SELECTED
Cohort	C1
Stratum	
Reason	Participant satisfies AGE AT REGISTRATION requirement: AGE_AT_REGISTRATION: 32, AGE_RANGE: >=18. Participant satisfies ECOG SCORE requirement: ECOG_SCORE: 2, MIN-MAX_VALUE: 0-2. Participant satisfies HR STATUS requirement: HR_STATUS: POSITIVE, CRITERIA: 'POSITIVE'. Participant satisfies HER2 STATUS requirement: HER2_STATUS: NEGATIVE, CRITERIA: 'NEGATIVE'. Participant matches to inclusion variant category: GENE_SYMBOL: NF1, MOLECULAR_CONSEQUENCE: 'frameshift', 'nonsense', VARIANT_CLASS: Deleterious, PROTEIN_HGVS: NP_001035957.1:p.Leu307GlnfsTer10. Participant matches to inclusion disease: TOPOGRAPHY_SITE: C50, BEHAVIOR_CODE: 3. Participant matches to prior therapy inclusion on DRUG ID: DRUG_ID: C97660. There are no PRIOR THERAPY EXCLUSIONS specified for this TREATMENT PROTOCOL. There are no DISEASE EXCLUSIONS specified for this TREATMENT PROTOCOL. There are no VARIANT EXCLUSIONS specified for this TREATMENT PROTOCOL.

Treatment Study Enrollment(s): Patient has not enrolled on any treatment trial(s)

Mockup of the Proposed Screen in OPEN



Reassignment Workflow



Review Cohort/Strata Updates

Cohort/Stratification Workflow Change

Scenario: Discrepancy between SO1 protocol schema and MATCHbox for collection of cohort and strata

MATCHBox/Engineering	OPEN/Rave/RSS	Group Impacts
• Update UI Display of Treatment protocol to always show accrual counts by regimen at the protocol level and NOT at cohort/stratum levels • Updates to DD tests for both MM and TPS • Update to the MM Smoke tests to cover this specific case	• Disconnect the accrual count updates to the protocol application if there are no cohort/strata • Update the RN treatment assignment field to make the cohort/strata optional • Protocol Application • The current accrual count would always be zero	• All groups would need to track the accrual manually. • This data may be ingested into the system in the future (TBD)

Stakeholder Engagement Plan

Stakeholder Feedback

- Please provide all feedback by 2/23/24
- https://forms.office.com/g/Ly8UTMXvBt
- Any questions on feedback or issues with the form, please email the PMI Standards Mailbox (pmistandards@nih.gov)

Open Discussion

- Allison Booth: If a patient is not matched to a treatment trial, is there a way to get the feedback on why they were not matched. Would like this data for future workups
  - The physician's choice option will change where the choice will always be given if patient is ineligible.
  - If the assignment would determine that the participant was not ineligible for what the physician chose, then they would get an assignment reason why not. Assuming in most cases the physicians choice is assigned as they do prior research
  - Other option is reach out to the help desk to gather that information.

Open Discussion

- Link for stakeholder feedback; will update the date.

Next Steps

Communication

Contact the PMI Mailbox for any PMI related questions & comments

pmistandards@nih.gov

The project team will respond within 48 hours with a response or a follow up

PMI Wiki

https://wiki.nci.nih.gov/display/CDISC/Precision+Medicine+Initiative

All presentations, recordings, minutes, project documents and releases will be posted on this wiki

NATIONAL CANCER INSTITUTE

www.cancer.gov www.cancer.gov/espanol

Appendix

Target Timeline

Nov – Mid Dec 2022

Group Activities
- Develop Study-specific Rave CRFs

NCI Activities
- ComboMATCH UAT Matchbox Environment
- MyeloMATCH UAT Matchbox Environment
- MATCHBox & OPEN Integrations for UAT
- Prepare Beta Screening & Treatment ALS files

Mid Dec 2022

NCI Activities
- Release EC Templatev1
- Release Beta Screening Protocol ALS
- Release Beta Treatment Protocol ALS
- aMOI List Approval and MATCHBox Upload

Mid Dec to Jan 30, 2023

Group Activities
- UAT Testing

NCI Activities
- Iterative updates to test findings (show-stoppers)

Target Timeline

Jan 31, 2023

NCI Activities
- Release EC Template v1
- Release Prod Screening Protocol ALS
- Release Prod Treatment Protocol ALS
- Release Prod Central Study ALS
- Release NCI OPEN Integrations for Prod
- Release NCI Genexus Installation (MyeloMATCH)

Jan 31 to Feb 14, 2023

NCI + Group Activities
- Support Group Study Builds

Feb 14, 2023

NCI + Group Activities
- Launch BOTH Initiatives

Spring 2023

NCI Activities
- Release Additional ALS(s)

ComboMATCH Priority 1 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps	Primary Agent Name (P) Other Agent Name (O)
1	EAY191	Molecular Analysis for Combination Therapy Choice (ComboMATCH)	ECOG-ACRIN	8/15/2022 Approval on Hold	Revision 3 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	
2	EAY191-N4	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMATCH Treatment Trial	NRG	8/15/2022 Approval on Hold	Revision 4 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Olaparib (AZD2281) (747856) (O) Selumetinib (AZD6244 hydrogen sulfate) (748727)
3	EAY191-E4	A ComboMATCH Treatment Trial ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors	ECOG-ACRIN	8/26/2022 Approval on Hold	Revision 3 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Nilotinib (747599) (O) Paclitaxel (Taxol) (673089)
4	EAY191-N2	A ComboMATCH Treatment Trial EAY191-N2: Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1	NRG	8/26/2022 Approval on Hold	Revision 3 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Binimetinib (788187) (O) Fulvestrant (Faslodex) (719276)
5	EAY191-S3	Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors	SWOG	8/29/2022 Approval on Hold	Revision 4 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Ipatasertib (781451) (O) Paclitaxel (Taxol) (673089)

ComboMATCH Priority 2 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps	Primary Agent Name (P) Other Agent Name (O)
6	EAY191-A6	A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations	Alliance	Approval on Hold 9/14/2022	Rev 4 approved by CIRB on 10/24. CTEP currently reviewing stips.	(P) Binimetinib (788187) (O) OXALIplatin (Eloxatin) (266046) (O) 5-Fluorouracil (5-FU) (19893) (O)Leucovorin calcium (3590)
7	EAY191-A3	Palbociclib and Binimetinib in RAS-Mutant Cancers	Alliance	Approval on Hold 8/26/2022	Rev 2 sent to CIRB . Reviewed on 10/6, study team responding to stips	(P) Palbociclib (PD-0332991) (772256) (O) Binimetinib (788187)

ComboMATCH Priority 3 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps	Primary Agent Name (P) Other Agent Name (O)
8	EAY191-A2	Olaparib Plus Low-Dose Alpelisib for Breast Cancer	Alliance	In Review 4/4/2022	Rev 3 recv;d 10/19, currently with LR. Looks like it'll be another disapproval. Not yet sent to CIRB for initial review.	(P) Olaparib (AZD2281) (747856) (O) Alpelisib (BYL719) (801658)
9	EAY191-C1	Phase 2 Subprotocol of the Combination of a MEK Inhibitor and a Pan-RAF Inhibitor in Patients with Relapsed/Refractory Tumors Harboring Activating MAPK Pathway Mutations	COG	In Review 9/29/2022	Protocol reviewed at PRC 10/20; CR is being put together	(P) Selumetinib (AZD6244 hydrogen sulfate) (748727) (O) DAY101 (TAK-580, MLN-2480) (800798)
10	EAY191-E5	ComboMATCH Treatment Trial E5: A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors	ECOG-ACRIN	In Review 2/22/2022	Waiting for revision 2 since 9/28; reminder was sent to EA 10/24	(P) AMG 510 (Sotorasib) (825510) (O) Panitumumab (742319)
11	EAY191-N5	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N5: A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors A ComboMATCH Treatment Trial	NRG	In Review 11/22/2021	Rev 3 disapproval sent 10/15; waiting for Rev 4	(P) Neratinib (783782) (O) Palbociclib (PD-0332991) (772256)

MyeloMATCH Priority 1 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps
1	MYELOMATCH	Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials	SWOG	11/12/2021: Approval on Hold	CIRB Reviewed on 9/15, version with stips under CTEP review now.
2	MM1YA-S01	A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger with High-Risk (Adverse) Acute Myeloid Leukemia; A MYELOMATCH Clinical Trial	SWOG	9/2/2022: Approval on Hold	CIRB Reviewed on 9/15, version with stips under CTEP review now.
3	MM1YA-CTG01	A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial	CCTG	9/2/2022: Approval on Hold	CIRB Review Oct 6, responding to stips
6	MM1OA-EA02 (Concept)	A Randomized Phase II Study of HMA-Based Therapies for the Treatment of Older Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia: A myeloMATCH Treatment Trial	ECOG-ACRIN	8/29/2022: Approved, no protocol yet	Waiting for protocol

MyeloMATCH Priority 2 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps
4	MM2YA-EA01	Eradicating Measurable Residual Disease in Patients with Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial	ECOG-ACRIN	1/21/2022: In Review	Reviewed by CIRB, responding to stips
5	MM1OA-S02	A Randomized Phase II Study of Targeted Agents with the Oral DNMT1 Inhibitor Cedazuridine-Decitabine (ASTX727) for the Treatment of Newly Diagnosed TP53-Mutated Acute Myeloid Leukemia in Older Patients: A myeloMATCH Treatment Trial	SWOG	10/17/2022: In Review	Scheduled for PRC 11/4
7	MM1MDS-EA03 (Concept	ERADICATE MDS with TP53 Study: Efficacy of taRgeted Agents Combinations with Oral DNMT1 Inhibitor C-DEC (ASTX727) for TrEatment of Higher Risk myElodysplastic Syndromes with TP53 Mutations: A Non-Comparative, Parallel, Multi-Arm Phase 2 Study	ECOG-ACRIN	8/12/2022: Approval on hold, waiting for drug commitment	W+A6:G8aiting for Astex commitment, Genentech has provided commitment on 10/20

Review Schemas

EAY191-N4


Protocol N4
EAY191-N4
People with:
• RAS Pathway Mutant (KRAS, NRAS, HRAS, NF1, BRAF)
• AND Ovarian (including primary peritoneal and fallopian tube) OR Endometrial Cancer
• Excludes:
◦ Prior MEK inhibitors
◦ Prior PARP inhibitors with disease progression (Prior PARP inhibitors are allowed if there was no disease progression)
Cohort 1
EAY191-N4.C1
People with Ovarian (including primary peritoneal and fallopian tube) Cancer
N = 85
Cohort 2
EAY191-N4.C2
People with Endometrial Cancer
N = 80
R
Treatment Regimen 1
EAY191-N4.C1.R1
(Selumetinib + Olaparib)
Treatment Regimen 2
EAY191-N4.C1.R2
(Selumetinib)
Participants on Treatment Regimen 2 that progress are eligible to crossover to Treatment Regimen 1 in the same Cohort
Treatment Regimen 1
EAY191-N4.C2.R1
(Selumetinib + Olaparib)
Treatment Regimen 2
EAY191-N4.C2.R2
(Selumetinib)
KEY
R Randomization

EAY191-E4


Protocol E4
EAY191-E4
People with:
• Previous taxane therapy (metastatic setting)
• Excludes:
◦ Platinum-resistant epithelial serous ovarian cancer
◦ cKIT variants
◦ PDGFRA D842V variants
N = 40
Treatment Regimen 1
EAY191-E4.R1
(Nilotinib + Paclitaxel)

EAY191-N2- Draft



EAY191-S3


Protocol S3
EAY191-S3
People with:
• Advanced or metastatic non-breast solid tumors
• A mutation in AKT1/AKT2/AKT3
• Progressed on prior taxane therapy
Excludes:
• Mutations in KRAS, NRAS, HRAS or BRAF
• Prior AKT inhibitor
N = 33
Treatment Regimen 1
EAY191-S3.R1
(Paclitaxel + Ipatasertib)

MMIYA-CTG01 Draft